Braftovi 50 mg hard capsules

DRUG3 trials

Sponsors

Pfizer Inc., Grupo Espanol Multidisciplinar De Melanoma

Conditions

MelanomaNon-small Cell Lung CancerSolid tumors

Phase 2

C4221008 - A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Non-small Cell Lung Cancer

CompletedCTIS2024-515929-28-00

Pfizer Inc.Non-small Cell Lung Cancer

Start: 2019-08-02End: 2025-08-14Target: 59Updated: 2025-08-19

Phase II, single arm, multicentre clinical trial to evaluate the activity of encorafenib plus binimetinib followed by Cemiplimab And Fianlimab in patients with BRAF mutated melanoma and symptomatic brain metastases.

RecruitingCTIS2024-513375-40-00

Grupo Espanol Multidisciplinar De MelanomaMelanoma

Start: 2025-05-16Target: 33Updated: 2025-11-25

Phase 4

C4221026: ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES

Active, not recruitingCTIS2023-509408-13-00

Pfizer Inc.Solid tumors

Start: 2022-09-20Target: 46Updated: 2025-08-11